Lupin has launched Azilsartan Medoxomil Tablets (40mg & 80mg) in the U.S. The company secured 180-day generic drug exclusivity as the first to file. The U.S. market for this drug is estimated at USD 53.5 million annually.

Lupin Launches Azilsartan Medoxomil Tablets in U.S. with Exclusive Rights

Lupin Limited has launched Azilsartan Medoxomil Tablets in 40mg and 80mg strengths in the United States. The U.S. market for this drug is estimated at USD 53.5 million annually, based on IQVIA data as of April 2026.

Reader Takeaway: Exclusive rights offer competitive edge; monitor product uptake during exclusivity window.

What just happened

Lupin announced the launch of Azilsartan Medoxomil Tablets in the U.S.

Why this matters

This launch is significant as Lupin secured 'exclusive first-to-file' status, granting it 180-day generic drug exclusivity. This allows Lupin to market its generic version with reduced competition for a limited period.

The U.S. market for Azilsartan Medoxomil Tablets (RLD Edarbi) has an estimated annual sales value of USD 53.5 million.

The backstory

The launch expands Lupin's cardiovascular product portfolio in the U.S.

What changes now

Lupin gains a competitive advantage in the U.S. hypertension drug market for 180 days, aiming to capture a significant share.

Risks to watch

Investors should monitor the product's market penetration and revenue generation during the crucial 180-day exclusivity period.

Peer comparison

No direct peer launches mentioned in the filing, but Lupin's strategy focuses on complex and branded generics in the U.S.

Context metrics (time-bound)

• Market Size: USD 53.5 million (U.S. annual sales for Azilsartan Medoxomil Tablets, RLD Edarbi, as per IQVIA MAT April 2026).
• Exclusivity Period: 180 days of generic drug exclusivity.

What to track next

Investor focus should be on Lupin's sales performance during the exclusivity period and its strategy for sustained market presence post-exclusivity.